Cancer patients responded better to immunotherapy and had a better prognosis if their melanoma tumours contained specific clusters of B cells, according to new research from Lund University in Sweden. The study is published in Nature.
Source Lund University
Immunotherapy strengthens the immune system so that it can fight cancer more effectively. One type of immunotherapy is checkpoint therapy, that targets the checkpoints that exist to prevent the immune system from becoming too active. However, releasing these brakes on the immune system is necessary to fight certain types of cancer, something that can be done with antibodies.
But far from all patients are being helped by the treatment, and intensive research is underway to understand who benefits the most from checkpoint therapy, and how it can be made even more effective. A great deal of focus so far has been on the immune cells called T cells.
The new study sheds light on the role of another immune cell in immunotherapy: B cells. Researchers at Lund University, together with several other international research groups, have shown that clusters of B cells in melanoma tumors, so-called tertiary lymphoid structures, are linked to the prognosis.
“By studying tissue samples from 177 melanoma patients, we have been able to see that when these B-cell structures were present in the tumour, the patient had a better prognosis and responded better to immunotherapy”, says Göran Jönsson, the professor at Lund University who led the study.
It has previously been known that these structures are sometimes found in tumours, but it is only now that they have been linked to prognosis and treatment response. In the same issue, Nature has published two other research articles that involve the same B-cell structures, albeit in other tumours – soft tissue sarcoma and kidney cancer – where there was also an association with improved response to immunotherapy.
The results of the Lund study confirm that it is not only the T-cells that are important, but that the B-cells also play a role in the immune response against cancer cells.
“Now we want to continue with prospective studies and investigate whether it is possible to stimulate the immune system to form these structures in tumours, and thus improve the effect of immunotherapy”, concludes Ana Carneiro, chief physician at Skåne University Hospital and associate professor at Lund University, who also participated in the study.
Funders of the study include: The Swedish Cancer Society, Swedish Research Council, Berta Kamprad Foundation, Gustav V Jubilee Fund, Mats Paulsson Foundation, Stefan Paulsson Foundation, Danish Cancer Society, Aase och Einar Danielsens Fund, EU Horizon 2020 Marie Curie grant, Region Skåne.